Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
Management to host conference call
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 1581007. A live webcast of the conference call will be available online under "Events and Presentations" in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Taconic Biosciences Launches New Inflammatory Bowel Disease Models19.4.2018 14:00 | Pressemelding
RENSSELAER, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, announces the launch of several new inflammatory bowel disease (IBD) animal models. As a fully-licensed provider of CRISPR/Cas9 gene editing technology, Taconic scientists knocked out the mouse Il10 gene to generate a spontaneous colitis mouse models. The new knockout models were created on Taconic's B6 (C57BL/6NTac) and BALB/c (BALB/cAnNTac) backgrounds, and are available at both the Excluded Flora (EF) and Germ Free (GF) health standards. Beyond the scientific benefits, Taconic is also making them easy to access by offering these models to commercial, contract research organization (CRO), and academic institutions under a simple label license. This represents a departure from the license requirements for Il10 knockouts from other animal model providers. "In order for animal models to drive drug discovery they need to be both
Cisco ACI Is Data Center Solution of Choice for Service Providers Worldwide19.4.2018 14:00 | Pressemelding
Service providers deliver new cloud services more quickly and offer superior customer experience with the help of Cisco Application Centric Infrastructure SAN JOSE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Providing secure, differentiated and rapidly delivered cloud services to customers is a crucial requirement for today's service providers. To meet cloud infrastructure demands, global service providers are increasingly turning to the Cisco® Application Centric Infrastructure (Cisco ACI(TM)) , the industry-leading software-defined networking (SDN) solution. Cisco ACI reduces operational costs with an automated, policy-based programmable architecture, while improving scalability and security. In addition, new Cisco ACI multi-site management capability helps service providers to connect and manage multiple geographically distributed Cisco ACI fabrics and to move and manage workloads with a single pane of glass. Cisco ACI is being deployed worldwide by service providers such as NTT Com
FinancialForce Extends Professional Services Automation Leadership With its Spring 2018 Release19.4.2018 14:00 | Pressemelding
New features empower services organizations to run their businesses with greater predictability, assign best-fit resources at scale, and forecast projects with 360-degree insight. SAN FRANCISCO, April 19, 2018 (GLOBE NEWSWIRE) -- FinancialForce, the number one customer-centric ERP cloud vendor built on the Salesforce Platform, announced the availability of its latest version of Professional Services Automation, the highest customer-rated PSA solution for enterprise organizations. The Spring 2018 Release of PSA brings new functional capabilities to accelerate project staffing speed and accuracy; unify people and project data; enable better forecasting decisions; and enhance the overall user experience using the Salesforce Lightning framework. Fast, Accurate Resource Mapping With the Spring 2018 Release of PSA, project and resource managers can identify and assign best-fit resources with greater speed and accuracy. Through advanced skills filtering and search capabilities, including part
SpeeDx receives FDA clearance for Mycoplasma genitalium product19.4.2018 14:00 | Pressemelding
SYDNEY, Australia, April 19, 2018 (GLOBE NEWSWIRE) -- SpeeDx's Resistance Plus ® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company's recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company - SpeeDx Pty Ltd - as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the Resistance Plus MG assay.* The Resistance Plus MG Positive Control kit contains synthetic DNA to simulate Mycoplasma genitalium, as well as five mutations known to confer resistance to macrolide antibiotics. Macrolide-resistant M. genitalium is a challenging sexually transmitted infection (STI), and global management guidelines are currently being adapted to deal with the rise in resistance. "This is an important product in our portfolio," said Elisa Mokany, Chief Technology Officer for SpeeDx. "M. genitalium is very difficult
SEMAFO: Construction of Boungou Mine 91% Complete19.4.2018 13:00 | Pressemelding
Commissioning Advancing to Plan MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) announced that construction of the Boungou Mine in Burkina Faso is 91% complete, and commissioning activities are advancing well with 10% already completed at the end of March. Since launch of commissioning at the end of February, the crushing circuit equipment and water services have been tested and commissioned. The reclaim and grinding circuits, reagent and oxygen plants are also undergoing testing. Wet commissioning began at the end of March with the Corporation pumping water from the water storage facility to the raw water tanks for the processing plant. We are still in line to achieve our first gold pour early in the third quarter of 2018. As at March 31, 2018, the following milestones had been reached: Development on budget with US$194 million of the US$231 million capital expenditure incurred Construction of the mine 91% complete Completion of 98% of structural steel and
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 201819.4.2018 13:00 | Pressemelding
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments. To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeut
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom